Indometacin farnesil

From Wikipedia, the free encyclopedia
Jump to: navigation, search
Indometacin farnesil
Systematic (IUPAC) name
(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl [1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl]acetate
Clinical data
AHFS/ International Drug Names
Legal status
  • (Prescription only)
Routes of
Pharmacokinetic data
Metabolism To indometacin
Biological half-life 1.5 hours
Excretion Renal
CAS Registry Number 85801-02-1 YesY
ATC code None
PubChem CID: 5282183
ChemSpider 4445378 YesY
Chemical data
Formula C34H40ClNO4
Molecular mass 562.14 g/mol
 YesY (what is this?)  (verify)

Indometacin farnesil (INN) is a prodrug of the non-steroidal anti-inflammatory drug indometacin, designed to reduce the occurrence of side-effects by esterification of the carboxyl group on indometacin with farnesol. Indometacin farnesil was first approved in Japan in 1991, and is available in Japan and Indonesia, under the trade names Infree and Dialon respectively.

External links[edit]